Pharma’s Words Of Wisdom For Prospective Biotech Partners
Low Prices Not Changed The Foundations Of Dealmaking
Executive Summary
Stay patient and concentrate on building trust rather than the bank balance was one of the key pieces of advice offered by business development heads at Regeneron and Eli Lilly to start-ups attending the recent BIO-Europe meeting.
You may also be interested in...
Deal Watch: BMS Backs Out Of UniQure Gene Therapy Collaboration
The gene therapy firm announced that Bristol terminated a collaboration started in 2015. Nona follows its recent alliance with Moderna with a second collaboration, this time with Dragonfly.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Pharma Firms Welcome 'Pragmatic' EU Reforms But Concerns Persist
The European parliament has voted for legislation it says will lead to fairer, more accessible healthcare. The continent's drugmakers are still not wholly convinced.